secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2022-07-26T23:59:59+00:00
Accession:  0001599298-22-000084
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit Therapeutics appoints Dr. Maky Zanganeh as Co-CEO & President
--------------------------------------------------------------------

- Dr. Maky Zanganeh appointed Co-CEO & President effective July 25, 2022; formerly COO.
- Bob Duggan remains Chairman of the Board and CEO, co-leading with Zanganeh.
- Zanganeh previously COO at Pharmacyclics; led key deals including $21B sale to AbbVie and $1B ibrutinib collaboration.
- She has been on Summit's board since November 2020 and continues to serve.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929822000084/0001599298-22-000084-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929822000084/smmt-20220725.htm
  HTML page:      https://secwatch.observer/filing/0001599298-22-000084

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer